Increased number of IL-2, IL-2 receptor and IL-10 positive cells in premalignant lesions of the cervix

Investigacion Clinica

Volumn 49, Issue 4, 2008, Pages 533-545

  Mindiola, Raimy ^a   Callejas, Diana ^a   Núñez Troconis, José ^b   Araujo, Mary ^a   Delgado, Mariela ^b   Mosquera, Jesús ^a,c  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b Hospital Chiquinquirá   (Venezuela)

^c Hospital Chiquinquirá e ^*  (Venezuela)

Author keywords

Cervix; IL 10; IL 2; IL 2 receptor; Premalignant lesions

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; VIRUS DNA;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VERRUCA VULGARIS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PRECANCER; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RECEPTORS, INTERLEUKIN-2; UTERINE CERVICAL NEOPLASMS;

EID: 61549122661     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Richart RM. Cervical intraepithelial neoplasia. En: Sommers, Ed. Pathology Annual S.C. New York, USA; 1997. P 301-328.
2. Apgar BS, Brotzman G. Management of cervical cytologic abnormalities. Am Fam Physician 2004; 70:1905-1916.
3. Moss RB, Moll T, El-Kalay M, Kohne C, Soo Hoo W, Encinas J, Carlo DJ. Th1/ Th2 cells in inflammatory disease states: therapeutic implications. Expert Opin Biol Ther 2004; 4:1887-1896.
4. Bauer H M, Ting Y, Greer CE, Chambers JC, Tashiro C J, Chimera J, Reingold A, Manos MM. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991; 265:472-477.
5. Hildesheim A, Schiffman MH, Gravitt P E, Glass A G, Greer C E, Zhang T, Scott DR, Rush BB, Lawler P, Sherman M E, Kurman R J, Manos MM. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235-240.
6. Mocellin S, Wang E, Marincola FM. Cytokines and Immune Response in the Tumor Microenvironment. J Immunother 2001; 24:392-407.
7. Al-Saleh W, Giannini SL, Jacobs N, Moutschen M, Doyen J, Boniver J, Delvenne P. Correlation of T-helper secretory differentiation and types of antigen- presenting cells in squamous intra- epithelial lesions of the uterine cervix. J Pathol 1998; 184:283-290.
8. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, Parham GP, Cannon MJ. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 2000; 74:4729-4737.
9. Grimm E, Mazumder A, Zhang H, Rosenberg S. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823-1841.
10. Rosenberg SA, Spiess P, Lafreniere R.A new approach to the adoptive immuno- therapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318-1321.
11. Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K. High-dose recombi- nant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
12. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high- dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-696.
13. Rocha-Zavaleta L, Huitron C, Caceres- Cortes JR, Alvarado-Moreno JA, Valle-Mendiola A, Soto-Cruz I, Weiss- Steider B, Rangel-Corona R. Interleukin-2 (IL-2) receptor-betagamma signalling is activated by c-Kit in the absence of IL-2, or by exogenous IL-2 via JAK3/STAT5 in human papillomavirus-associated cervical cancer. Cell Signal 2004; 16:1239-1247.
14. Giannini SL, Al-Saleh W, Piron H, Jacobs N, Doyen J, Boniver J, Delvenne P. Cytokine expression in squamous intra- epithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immuno 1998; 113:183-189.
15. Rafiq KL, Charitidou DMA, Bullens A A, Kasran K, Lorre J L, Ceuppens J, Van Gool S W. Regulation of the IL-10 production by human T cells. Scand J Immunol 2001; 53:139-147.
16. Mocellin S, Panelli M, Wang E, Rossi CR, Pilati P, Nitti D, Lise M, Marincola FM. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun 2004; 5:621-630.
17. Graffen SL, Lai SY, Xu W, Gouilleux F, Groner B, Goldsmith MA, Greene WC. Signalling through the interleukin-2 receptor β chain activates a stat-5-like DNA- binding activity. Proc Natl Acad Sci USA 1995; 92:7192-7196.
18. de Gruijl TD, Bontkes HJ, van den Muysenberg AJ, van Oostveen JW, Stukart MJ, Verheijen RH, van der Vange N, Snijders PJ, Meijer CJ, Walboomers JM, Scheper RJ. Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer 1999; 35:490-497.
19. Hubert P, van den Brule F, Giannini SL, Franzen-Detrooz E, Boniver J, Delvenne P. Colonization of in vitro-formed cervical human papillomavirus- associated (pre) neoplastic lesions with dendritic cells: role of granulocyte/macrophage colony-stimulating factor. Am J Pathol 1999; 154: 775-784.
20. Inoue T, Iwasaki K, Chihara T, Torisu M. Cervical carcinoma and eosinophil I. Eosinophil chemotactic factor derived from invasive cervical carcinoma with eosinophil infiltration. Clin Immunol Immunopathol 1981; 21:320-331.
21. Megiovanni AM, Sanchez F, Gluckman JC, Rosenzwajg M. Double-stranded RNA stimulation or CD40 ligation of monocyte- derived dendritic cells as models to study their activation and maturation process. Eur Cytokine Netw 2004; 15:126-134.
22. Azzarone B, Pottin-Clemenceasu C, Krief P, Rubinstein E, Jasmin C, Scudeletti M, Indiveri F. Are interleukin-2 and interleukin-15 tumor promoting factors for human non-hematopoietic cells? Eur Cytokine Netw 1996; 7:27-36.
23. Reichert T, Watkins S, Stanson J, Johnson JT, Whiteside TL. Endogenous IL-2 in cancer cells: a marker of cellular proliferation. J Histochem Cytochem 1998; 46: 603-611.
24. El-Sherif AM, Seth R, Tighe PJ, Jenkins D. Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. Am J Pathol 2001; 195:179-185.
25. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, Venzon DJ, Shearer GM, De Palo G, Clerici E. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997; 89:245-250.
26. Critchlow CW, Koutsky, LA. Epidemiology of human papillomavirus infection. En: Mindel A, Ed. Genital warts: human papillomavirus infection. London: Edward Arnold; 1995. P 53-81.
27. von Knebel Doeberitz M. The role of papillomaviruses in the etiology of cervix cancer. Geburtshilfe Frauenheilkd 1990; 50:511-517.
28. Muñoz M, Mendoza JA, Tellez L, Noguera ME, Moret O, López M, Toro M. Detec- cion de VPH-16 y 18 en muestras de cérvix de mujeres que acuden a centros asisten- ciales de la ciudad de Mérida, Venezuela. Rev Biomed 2003; 14:61-68.
29. Mendoza JA, Muñoz M, Vielma S, Noguera ME, López M, Toro M. Infección cervical por el virus del papiloma humano: diag-nóstico por citología y por captura de hí- bridos del ADN viral. Rev Obstet Ginecol Venez 2000; 60:103-107.
30. Zarcone R, Bellini P, Cardone G, Barletta E, Vicinanza G. Association of interleukin 2 and interferon alpha in the management of cervical condylomatosis. Minerva Gine- col 1996; 48:111-113.
31. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000; 182:595-598.
32. Ung A, Kramer TR, Schiffman M, Herrero R, Bratti MC, Burk RD, Swanson CA, Sherman ME, Hutchinson ML, Alfaro M, Morales J, Balmaceda I, Hildesheim A. Soluble Interleukin 2 Receptor Levels and Cervical Neoplasia. Results from a Population-based Case-Control Study in Costa Rica. Cancer Epidemiol Biomark Prev 1999; 8:249-253.